Article
Myeloid-specific KDM6B inhibition sensitizes Glioblastoma to PD1 blockade
2022-11-29
Abstract excerpt
Glioblastoma (GBM) tumors are enriched in immune-suppressive myeloid cells and are refractory to immune checkpoint therapy (ICT). Targeting epigenetic pathways to reprogram the functional phenotype of immune-suppressive myeloid cells to overcome resistance to ICT remains unexplored. Single-cell and spatial transcriptomic analyses of human GBM tumors demonstrated high expression of an epigenetic enzyme - histone 3...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 081f2fcf-5da0-5b3c-bb89-72dd77f2c538
- DOI
- 10.1101/2022.11.28.518243
